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ABSTRACT 
Objective: This study intends to design software algorithms, which is called Co-Drug Interaction (CODI), that able to analyse drug interactions in 
prescription and recommendations for further correction by replacing active substances based on the E-book Drug Interaction Facts and provide 
drug information features.  
Methods: The research used data collection and conversed into programming languages. Java language programme choosed to build the entire 
application as its considerable free of charge and recognizable interface to use. The reference book is also used to help in prescribing and evaluating 
the reliability and efficiency of the software. 
Result: The evaluations were performed by analyzing 30 groups of medicine based on 2 diseases, which are hypertension and diabetes mellitus.  
Conclusion: The algorithm design and evaluation are in accordance with the planned output. 
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INTRODUCTION 
Drug interactions and its side effects are still an ongoing problem, 
whether in the clinical or the community scope. This will be 
exacerbated by the use of more than 1 type of drug that will lead to 
undesirable polypharmacy prescription. It is known that the use of 
many drugs at one time has the potential for drug interactions. the 
role of pharmacists is needed to prevent this event from occurring as 
long as disease management is still using drugs [1, 2]. In a drug 
prescription, it is necessary to check drug interactions and requires 
knowledge regarding to the types of drug interactions that will need 
a lot of references. However, there a few pharmacies that do not 
have the books. For instance, the software is needed in pharmacist 
work place because it can combine information efficiently to check 
drug interactions. In recent time, a lot of software has been made, 
but to use the software is still using the internet which is less helpful 
in remote area where there is no insufficient infrastructure to 
delivering internet connection. 
Utilization of technology and the internet at this time can no longer 
be stopped, including in the health sector. People have always had to 
go to the primary health care or clinic, even for minor symptoms. 
Maybe without realizing it, those situation sacrificed time, effort, and 
bill at an inconsiderable price. In emergency situations, especially 
for the elderly and children, must be addressed immediately before 
they have a worse impact. The use of information systems is 
expected to increase service efficiency without compromising 
patient safety [3]. In the pharmaceutical field, the software is widely 
used, for example, checking drug interactions (Medscape) from the 
https:// reference.medscape.com/drug interaction checker, 
(Uptodate) site from https://www.uptodate.com/, and others. Using 
the site as the source of information has its limitations to get 
internet access. Meanwhile, the UpToDate website can be accessible 
by paying an amount of fee, which it is not affordable for everyone.  
This research aim is to develop a software called CODI (Co-Drug 
Interaction) to help analyze prescriptions received by patients and 
assist drug information services by offline and particularly built to give 
a hand to the pharmacist in the rural area. CODI (Co-Drug Interaction) 
is made with Java programming language which will be composed of 
several features, including features of drug interaction analysis, drug 
information features and recommendation features if there is an 
interaction in a prescription to analyze prescription drugs based on 2 
disorder, which are hypertension and diabetes mellitus. 
The diseases are choosen as its one of the most common diseases in 
Indonesia. Both of these diseases potentially using several drugs 
simultaneously and can point out to negative effect due to its 
interaction. According to Nurlaelah et al. (2015) [4], drug 
interactions in the treatment of type 2 diabetes mellitus with 
hypertension in the outpatient installation at Undata Hospital Palu 
stated that 52 patients experienced drug interactions with a general 
percentage of 85.2% and a percentage of drug interactions with 
pharmacokinetic mechanisms of 18.2%, drug interactions with 
pharmacodynamics were 72.7%, and drug interactions with 
unknown mechanisms were 9.1%. Antihypertensive drug 
interactions in primary hypertensive patients at the Luwuk Hospital 
Outpatient Installation for the January-March 2016 period were 
43.2% and the percentage of drug interactions with 
pharmacokinetic mechanisms was 10% and drug interactions with 
pharmacodynamics was 90% [5]. Description of potential drug 
interactions for diabetes mellitus in outpatient prescription drugs at 
Dr. Mintohardjo, from the results obtained by 310 prescription 
sheets, found that 204 prescription sheets (65.80%) experienced 
potential drug interactions and more interactions were found on 
prescription sheets that received drugs ≥5 kinds of drugs [7]. Based 
on the high rate of drug interactions in patients with hypertension 
and diabetes mellitus, it is necessary to create software to make it 
easier to analyze interactions on drug prescriptions in order to 
reduce the incidence of drug interactions that occur. 
MATERIALS AND METHODS 
Materials and tools 
Laptop Lenovo Ideapad 330 with Intel® Celeron® N4000 CPU @ 
1.10GHz (2 CPUs) (produced in Taiwan in 2018, bought in Indonesia 
at the same year), NetBeans IDE version 8.1 (released 16 November 
2015 worldwide), Mouse Logitech M221 wireless, Wifi, e-book Drug 
Information Handbook 17th Edition, e-book Drug Interaction Facts 
2009 e-book Top 300 Pharmacy Drug Cards, e-book British National 
Formulary 74th Edition, e-book High Blood Pressure-Medicines to 
Help You, and e-book Indonesian Pharmacopoeia Edition V. 
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Data collection providing CODI (Co-drug interaction) software 
This software requires information on drug interactions and 
recommendations to manage its interactions, dosages, indications, 
contraindications, storage, and side effects. This information can be 
found in e-book Drug Information Handbook 17th edition, e-book 
Drug Interaction Facts 2009, e-book Indonesian Pharmacopoeia V 
Edition, e-book Top 300 Pharmacy Drug Cards, e-book British 
National Formulary 74th Edition, and e-book High Blood Pressure-
Medicines to Help You. All of this data is combined with 
programming commands for each feature. 
Algorithm conversion to programming language providing 
CODI software 
The algorithm conversion to programming language providing CODI 
(Co-Drug Interaction) software can be seen in fig. 1. 
  
 
Fig. 1: Algorithm of suitability analysis features 
 
In the suitability analysis feature, drug interaction information data 
is combined with commands that directly analyze whether there are 
drugs interacting based on drug interaction information data. In this 
feature, the form design (display) of this feature is made in the form 
of a list to select active substances (fig. 2). 
The drug information feature contains dosage information, 
indications, contraindications, storage, and side effects based on 2 
diseases, namely hypertension and diabetes mellitus. This 
information is taken from references mentioned earlier; then the 
data is combined with programming commands (fig. 3). 
 
 
Fig. 2: Algorithm of drug information features 
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Fig. 3: Algorithm of recommendation feature 
 
This recommendation feature uses data management which is 
combined with commands that directly provide management 
information when there is an interaction based on data 
management. 
Evaluation of CODI (Co-drug interaction) software 
Evaluation is carried out by looking at the variable aspects of 
software quality, but there are some aspects that are not tested 
because they are not included in the scope of the usefulness of the 
CODI software, other than that, the evaluation is only strengthened 
in the simulation. Checking of active interacting substances and 
recommendations. The following is a table of the quality variables of 
the CODI software. 
Prescription drug analysis with CODI (Co-drug interaction) 
software 
The flowchart of the analysis of prescribing drugs with CODI 
software can be seen in fig. 4. 
 
Table 1: Software quality variables 
Sub variable Indicator 
Reliability (the ability of the software to 
carry out its functions) 
The active substance selection test was designed by designing 30 groups of active substances based on 
2 diseases, namely hypertension and diabetes mellitus, listed in the Drug Interaction Facts. 
Efficiency (the computational resources 
required by the software to perform its 
functions) 
The accuracy of the command form and the access button to the command by pressing each access 
button to the command and seeing the suitability of the command carried out by the CODI (Co-Drug 
Interaction) software. The efficiency evaluation sheet is included in the attachment. 
 
 
Fig. 4: Analysis of prescribing drugs with CODI software 
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RESULTS AND DISCUSSION 
Making CODI (Co-drug interaction) software 
CODI (Co-Drug Interaction) software was created using the 
NetBeans IDE with the Java programming language. A 
programming language is the instructions understood by the 
computer to perform certain tasks. The Java language was 
developed at Sun Microsystems and was introduced to the public 
in 1995; just like C++, Java is also an object-oriented language; 
thus, Java also makes it easy to build large-scale applications. As 
a high-pitched language, which uses commands that are easily 
understood by people [6]. 
 
 
Fig. 5: Coding display following the algorithm design 
 
In the coding process, the features are made according to the 
algorithm design (fig. 5). In the algorithm design, interaction checks 
and recommendations when interactions occur are described by 
selecting the active substance that you want to know first, then 
determining what information you want to know. The input of active 
substances that you want to know is five entries, which are the 
advantages of this software which aims to increase the active 
substance that you want to know the interaction and 
recommendations if there is an interaction when the active 
substances are used together, recommendation information if an 
interaction occurs is an advantage of this software because in 
general, other software rarely provides this information. The 
suitability analysis feature (fig. 6) and the recommendation feature 
have the same input because in this case, the active substance that 
you want to know is the same so that the input is made the same for 
ease of use. 
 
 
Fig. 6: Input on the suitability analysis feature and the recommendation feature 
 
To check drug information, first pressing the drug information button 
then selecting the active substance you want to know, then determining 
what information you want to know, the available information includes 
indications, contraindications, dosage, side effects, and storage; the 
information results can be seen in fig. 7. All drug information provided is 
in Indonesian, making it easier to analyze drug prescriptions. 
 
 
Fig. 7: Input on the drug information feature and result information 
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Fig. 8: Output results in the form of a PDF file 
 
Evaluation of CODI (Co-drug interaction) software 
At this stage, as many as 30 groups of active substances for 
hypertension and diabetes mellitus were made; the output is in the 
form of a PDF file as shown in fig. 8 below. 
To find out that the results of the analysis of the suitability analysis 
feature and recommendation features when an interaction occurs is 
valid, the results are compared with the interaction data and 
recommendations for each active substance with each other active 
substance based on data from the e-book Drug Interaction Facts 
(2009) [8]. 
In the first group, there are active substances used, namely lisinopril, 
bisoprolol, glimepiride and metformin; the second group has active 
substances used, namely candesartan, amlodipine, and metformin, 
and the third group of active substances used are acarbose, 
metformin, nadolol, nifedipine, and valsartan., where each active 
substance used is compared with other active substances based on 
existing data on the Drug Interaction Facts in order to know the 
interactions and recommendations if there is an interaction of all 
active substances used. 
After comparing the results of the CODI (Co-Drug Interaction) 
Software output on existing features with drug interaction data and 
recommendations from Drug Interaction Facts, it can be seen that 
the results of the analysis in the first, second, and third groups are in 
accordance with the interaction data and their recommendations. 
The first group is glimepiride, which interacts with lisinopril, the 
second group is that there is no interaction, and the third group is 
metformin which interacts with acarbose and nadolol which 
interacts with nifedipine. According to Tatro (2009) 
glimepiride+lisinopril provides an interaction, namely the risk of 
hypoglycemia can be increased and its recommendations namely 
carefully observing the symptoms of hypoglycemia when starting 
ACE Inhibitor therapy in patients receiving Sulfonylurea therapy 
[8,9]. Nadolol+nifedipine provides an interaction; namely, the 
pharmacological effects of both drugs can be strengthened and the 
recommendation is to carefully monitor the cardiac function of 
patients with risk of side effects [10]. The largest cardiovascular and 
metforim+acarbose provide the interaction ie the onset of 
metformin effects may be delayed after the initial dose and the 
recommendation is that based on available data no special 
precautions are required [11]. 
In evaluating the suitability of the button with the command form, 
there were no errors found. Each button describes its commands 
well. 
CONCLUSION 
Based on the research that has been done, it can be concluded that 
The design of the CODI (Co-Drug Interaction) software algorithm is 
in accordance with the output of the software in the form of a list of 
active substances used, along with its interactions and 
recommendations based on the active substances selected. The 
results of reliability testing by designing 30 groups of active 
substances based on 2 diseases, namely hypertension and diabetes 
mellitus, are in accordance with the comparison of interaction data 
and recommendations based on data from the e-book Drug 
Interaction Facts so that it can be stated that the results of CODI (Co-
Drug Interaction) analysis is valid. Likewise, in testing efficiency by 
looking at the suitability of the button and the shape of the 
command, it can be stated that it is appropriate to use. 
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